Simvastain Affects TAFI and Thrombomodulin in CAPD Patients

• References

• 1 Locatelli F, Del Vecchio L, Manzoni C. Morbidity and mortality on maintenance hemodialysis. Nephron 1998; 80: 380-400.
• 2 Llach F. Hypercoagulability, renal vein thrombosis and other thrombotic complications of nephrotic syndrome. Kidney Int 1985; 28: 429-33.
• 3 Matthys E, Schurgers M, Lamberigts G, Lameire N, Vandecasteele N, Labeur C, Beisiegel U, Rossenau M. Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients. Atherosclerosis 1998; 86: 183-192.
• 4 Sagripanti A, Barsotti G. Bleeding and thrombosis in chronic uremia. Nephron 1997; 75: 125-39.
• 5 Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997; 78: 386-91.
• 6 Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
• 7 Bajzar L, Nesheim ME, Morser J, Tracy PB. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998; 273: 2793-8.
• 8 Schatteman KA, Goossens FJ, Scharpe SS, Neels HM, Hendriks DF. Assay of procarboxypeptidase U, a novel determinant of fibrinolytic cascade, in human plasma. Clin Chem 1999; 45: 807-13 158-65.
• 9 Malyszko J, Malyszko JS, Mysliwiec M. Comparison of hemostatic disturbances between patients on CAPD and HD. Perit Dial Int 2001; 21: 158-65.
• 10 Tomura S, Nakamura Y, Doi M, Ando R, Ida T, Chida Y. et al. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1996; 27: 848-54.
• 11 Kobayashi M, Yorioka N, Yamakido M. Hypercoagulability and secondary hyperfibrinolysis may be related to abnormal lipid metabolism in patients treated with continuous ambulatory peritoneal dialysis. Nephron. 1997; 76: 56-61.
• 12 Sokunbi DOB, Wadhwa NK, Suh H. Vascular disease outcome and thrombocytosis in diabetic and nondiabetic end-stage renal disease patients on peritoneal dialysis. Adv Peri Dial 1994; 10: 77-80.
• 13 Rustom R, Leggat H, Tomura HR, Hay CR, Bone JM. Plasma thrombomodulin in renal disease: effects of renal function and proteinuria. Clin Nephrol 1998; 50: 337-413.
• 14 Hosaka Y, Takahashi Y, Ishii H. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma. Thromb Haemost 1998; 79: 371-7.
• 15 Yorioka N, Masaki T, Ito T, Kushikata S, Nishida Y, Taniguchi Y, Oda H, Yamakido M. Lipid-lowering therapy and coagulation/fibrinolysis parameters in patients on peritoneal dialysis. Int J Artif Organs 1998; 23: 27-32.
• 16 Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int 1999; 56 (Suppl. 71) S2-S5.